



## KINDReD Consortium

The FP7-funded Kinetoplastid Drug Development (KINDReD) consortium has been created to strengthen and advance the current drug development pipeline in neglected infectious diseases. The consortium's key objective is to bring promising anti-trypanosomatid drug discovery initiatives forward by combining the strengths of key experts in industry and academia to create a unique and powerful drug discovery platform with the common goal of advancing promising laboratory-driven discoveries into clinical utility.

The KINDReD consortium integrates leading academic laboratories in Europe (Portugal, United Kingdom, France and Switzerland), the USA (California), India and South America (Brazil) with high throughput screening (HTS) facilities equally distributed between all three major kinetoplastid parasites. CDD Vault is the collaborative data management platform used across all consortium members.

